Healthcare

Immutep’s Breakthrough Immunotherapy Delivers Strong Survival Gains in ASX200 Cancer Trial
May 05, 2025 02:54 PM AEST| By Team Kalkine MediaHighlights,Strong survival outcomes in head and neck cancer trial,Potential step forward in chemotherapy-free immunotherapy,Addresses high unmet need in immune-resistant tumours,Immutep (ASX:IMM),has released promising results from its Phase IIb TACT...

Can Sonic Healthcare’s ROE Trends Reflect Broader ASX200 Healthcare Sector Signals?
May 05, 2025 02:32 PM AEST| By Team Kalkine MediaCan Sonic Healthcare’s ROE Trends Reflect Broader ASX200 Healthcare Sector Signals?

Healius Boosts Shareholder Returns with $300 Million Special Dividend: A Positive Signal in ASX200
May 05, 2025 02:30 PM AEST| By Team Kalkine MediaHighlights,Healius announces fully franked special dividend.,Distribution totals approximately $300 million.,Share price rises over 4% following announcement.,Healthcare and diagnostic services provider,Healius,(ASX:HLS) has announced a significant m...

Cadoux (ASX:CDX) Powers Ahead in HPA and Rare Earths with Strategic Moves and ASX200 Growth Potential
May 05, 2025 12:53 PM AEST| By Team Kalkine MediaHighlights,FEED studies initiated for high purity alumina plant,Minhub feasibility study completed in Darwin,Focus on EV, battery, and rare earth market demand,Cadoux Ltd (ASX:CDX),made notable strides during the March 2025 quarter, progressing its H...

Biotech Breakthrough and ASX 200 Movement: ATH, GOR, HZR Drive Industry Updates
May 05, 2025 11:30 AM AEST| By Team Kalkine MediaHighlights,Alterity Therapeutics (ASX:ATH) receives Fast Track designation from the U.S. FDA for a rare neurological disorder treatment,Gold Road Resources (ASX:GOR) enters strategic agreement with Gold Fields to advance sector consolidation,Hazer Gr...

Alterity Therapeutics (ASX:ATH) Gains FDA Fast-Track Status Amid ASX 200 Biotech Developments
May 05, 2025 11:30 AM AEST| By Team Kalkine MediaHighlights:,Alterity Therapeutics (ASX:ATH) received FDA fast-track designation for its neurological therapy ATH434,Trading volume surged on the ASX and NASDAQ amid high share activity,Biotech sector, including Alterity, aligns with broader developme...

Why Cochlear (ASX:COH) May Be a Standout in ASX200 Healthcare Stocks in 2025
May 05, 2025 10:41 AM AEST| By Team Kalkine MediaHighlights,COH shares trade below historical valuation,Healthcare sector shows stable, long-term potential,Growing appeal for ethical and sustainable investing,Cochlear (ASX:COH), the global leader in hearing implant technology, has seen its share pr...

Key Insider Activity at Althea Group Holdings (ASX:AGH) – Insight on Recent Developments
May 03, 2025 02:34 PM AEST| By Team Kalkine MediaHighlights:,CEO Joshua Fegan made a significant stock purchase in Althea Group Holdings (ASX:AGH).,Over the last year, the company experienced a net buying trend in insider transactions.,Despite strong insider alignment, there are notable concerns re...

Sigma Healthcare's Post-Merger Momentum: What's Driving Investor Interest in this ASX200 Stock
May 02, 2025 04:01 PM AEST| By Team Kalkine MediaHighlights,Sigma Healthcare's growth outlook shines post-Chemist Warehouse merger,Valuation premium seen as justified by strong defensive earnings,11% upside potential highlighted by analysts,Sigma Healthcare (ASX:SIG) is gaining renewed attention fo...

Island Pharmaceuticals ASX:ILA Transactions: Ownership and Share Trends Reviewed | ASX All Ordinaries & ASX 200
May 02, 2025 02:35 PM AEST| By Team Kalkine MediaHighlights,Market capitalization increased significantly for Island Pharmaceuticals (ASX:ILA) during the year,Company insiders showed more buying activity than selling over the review period,Ownership by company insiders remains a substantial portion...

Ownership Breakdown of Healius Limited (ASX:HLS) and Its Market Dynamics
May 02, 2025 02:32 PM AEST| By Team Kalkine MediaHighlights,:,Institutional investors own a major portion of Healius.,Private equity firms possess a significant stake in the company.,Insiders and the general public hold relatively smaller shares,Healius Limited (ASX:HLS) is a key player in the heal...

Is Biotech Volatility Reshaping Imugene's Path in the ASX All Ordinaries Index?
May 02, 2025 01:30 PM AEST| By Team Kalkine MediaIs Biotech Volatility Reshaping Imugene's Path in the ASX All Ordinaries Index?

CSL (ASX:CSL): Is This Healthcare Giant Still a Staple in ASX200?
May 02, 2025 12:55 PM AEST| By Team Kalkine MediaHighlights,CSL revenue grows at 12.8% CAGR over three years,Profit reaches $2.64 billion in FY24,Debt/equity ratio,remains,balanced at 62.8%,Shares of biotechnology heavyweight,CSL (ASX:CSL),have seen a decline of 10.69% since the start of 2025, spar...

Race Oncology Reaches Critical Trial Milestone with RC220 Cancer Drug
May 02, 2025 11:10 AM AEST| By Team Kalkine MediaHighlights,First patient dosed in Phase 1 RC220 trial,Breakthrough formulation,eliminates,prior safety concern,Global trial expansion planned in 2025,Race Oncology (ASX:RAC) has marked a significant milestone with the successful dosing of the first p...

Healius (ASX:HLS) Surges on ASX 200 After $822 Million Imaging Unit Sale
May 01, 2025 06:29 PM AEST| By Team Kalkine MediaHighlights,Healius rallies post Lumus Imaging divestment,$822 million cash proceeds boost company momentum,Special dividend announced as part of reshaping strategy,Healius (ASX:HLS), a prominent player in Australia's healthcare sector, saw its shares...

ASX Health Sector Update: ILA, TYP, DXB, OIL Drive Innovations on All Ordinaries
May 01, 2025 04:33 PM AEST| By Team Kalkine MediaHighlights:,Island Pharmaceuticals completed Phase 2a/b dengue trial and advanced Galidesivir acquisition,Tryptamine Therapeutics progressed psilocin-based TRP-8803 in binge eating disorder trial,Dimerix secured DMX-200 licensing deals and advanced P...

Imugene Ramps Up Clinical Momentum Amid Strong Trial Results and ASX 200 Positioning
May 01, 2025 03:55 PM AEST| By Team Kalkine MediaHighlights,Imugene reports strong trial outcomes for azer-cel in DLBCL,Fast Track Designation granted by US FDA for azer-cel therapy,Expanded patents and improved cash reserves boost growth potential,Imugene Ltd (ASX:IMU) advanced significantly in th...

Dimerix Secures Major US Partnership for Kidney Drug Amid Growing ASX 200 Healthcare Momentum
May 01, 2025 02:29 PM AEST| By Team Kalkine MediaHighlights,Dimerix inks US licensing deal with Amicus for kidney drug DMX-200,Agreement includes up to US$560 million in milestone payments,Addresses urgent need for treatment in rare kidney disease FSGS,Australian biotech company Dimerix (ASX:DXB) h...

EVE Health Makes Bold Therapeutics Pivot with Nextract Deal, Tapping Into Multi-Billion-Dollar Markets | ASX 200 Watch
May 01, 2025 02:16 PM AEST| By Team Kalkine MediaHighlights,EVE Health pivots into global therapeutics with Nextract acquisition,Targets erectile dysfunction and period pain markets,Launch plans underway with expansion into MENA region,EVE Health (ASX:EVE) is embarking on a transformative journey,...

ASX 200 Short Interest Review: BHP, Sigma Pharmaceuticals, and Alcoa Movement Overview
April 30, 2025 10:15 PM AEST| By Team Kalkine MediaHighlights:,Short interest trends observed across,BHP Group,(ASX:BHP), Sigma Pharmaceuticals (ASX:SIP), and Alcoa Corporation (ASX:AAI),Shifts recorded in overall short positioning across selected stocks in the materials and healthcare sectors,Weekly...

Advertise your brand on Kalkine Media